Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,878,706
  • Shares Outstanding, K 166,253
  • Annual Sales, $ 1,476 M
  • Annual Income, $ 241,660 K
  • EBIT $ 254 M
  • EBITDA $ 281 M
  • 60-Month Beta 0.53
  • Price/Sales 3.40
  • Price/Cash Flow 18.01
  • Price/Book 2.74

Options Overview Details

View History
  • Implied Volatility 50.23% (+0.45%)
  • Historical Volatility 58.92%
  • IV Percentile 27%
  • IV Rank 16.70%
  • IV High 112.83% on 07/17/25
  • IV Low 37.67% on 09/09/25
  • Expected Move (DTE 16) 2.71 (7.57%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 212
  • Volume Avg (30-Day) 388
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 7,873
  • Open Int (30-Day) 6,854
  • Expected Range 33.10 to 38.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 1
  • High Estimate $-0.12
  • Low Estimate $-0.12
  • Prior Year $0.13
  • Growth Rate Est. (year over year) -192.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.00 +32.92%
on 03/19/26
36.29 -1.11%
on 04/01/26
+5.79 (+19.23%)
since 02/27/26
3-Month
27.00 +32.92%
on 03/19/26
36.29 -1.11%
on 04/01/26
+7.91 (+28.26%)
since 12/31/25
52-Week
25.17 +42.61%
on 09/08/25
36.32 -1.19%
on 11/05/25
+3.36 (+10.32%)
since 04/01/25

Most Recent Stories

More News
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy...

ALKS : 35.67 (+0.88%)
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse...

ALKS : 35.67 (+0.88%)
Alkermes: Q4 Earnings Snapshot

Alkermes: Q4 Earnings Snapshot

ALKS : 35.67 (+0.88%)
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full...

ALKS : 35.67 (+0.88%)
Alkermes plc Announces CEO Succession Plan

— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive...

ALKS : 35.67 (+0.88%)
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026 at 9:10...

ALKS : 35.67 (+0.88%)
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

— Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ ® (Sodium Oxybate) for Extended-Release Oral Suspension...

AVDL : 21.64 (+0.05%)
ALKS : 35.67 (+0.88%)
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end...

ALKS : 35.67 (+0.88%)
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1),...

ALKS : 35.67 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 40.55
2nd Resistance Point 38.39
1st Resistance Point 36.87
Last Price 35.67
1st Support Level 33.19
2nd Support Level 31.03
3rd Support Level 29.51

See More

52-Week High 36.32
Last Price 35.67
Fibonacci 61.8% 32.06
Fibonacci 50% 30.74
Fibonacci 38.2% 29.43
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.